Trevi Therapeutics announced the closing of its previously announced underwritten public offering, raising approximately $115.1 million in total proceeds before deducting underwriting discounts and commissions. The offering included 20,010,000 shares of common stock priced at $5.75 per share.
The total shares issued included 2,610,000 additional shares from the full exercise by the underwriters of their option to purchase additional common stock. All shares in the offering were sold by Trevi.
This successful capital raise significantly strengthens the company's financial position, providing critical funding to advance its investigational therapy Haduvio through ongoing and planned clinical trials for chronic cough in IPF and RCC.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.